Research by Parkinson’s UK indicates that around 166,000 patients are affected by the neurological condition in the nation, with this figure standing at around 2.2 million in Europe.
Parkinson’s disease is viewed as the fastest growing neurological disorder globally, as per the World Health Organization (WHO), with further research projecting that the global incidence of the disease could exceed 30 million by 2050, almost doubling numbers recorded in 2021.
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
For the UK and Europe, the annual economic impact of Parkinson’s disease is vast, at around £3.6bn ($4.8bn) and €22.8bn ($25.49bn), respectively.
With this in mind, there is an increasing drive to ensure patients with the disease are able to access advanced therapies such as deep-brain stimulation (DBS). Such approaches to Parkinson’s have been demonstrated to improve patients’ quality of life (QoL).
However, in the UK, recent research conducted by Boston Scientific on 60 healthcare professionals (HCPs) found that despite their belief in the clinical efficacy of DBS, nine in 10 (88%) of the respondents did not believe it reaches all UK patients who could benefit.
In this episode, Ross Law, editor for Medical Device Network, was joined by Vincent Sourdaine, vice president, neuromodulation in Europe, Middle East and Africa (EMEA) at Boston Scientific, and Francesco De Renzis, partnerships director at Parkinson’s Europe, to learn more about the problems associated with DBS access in the UK and across Europe, among other themes that arose from Boston Scientific’s recent survey.
Listen to the full episode below:
